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Background: Diabetes may confer an increased risk for the cardiovascular health effects of particulate air pollution,
but few human clinical studies of air pollution have included people with diabetes. Ultrafine particles (UFP,
≤100 nm in diameter) have been hypothesized to be an important component of particulate air pollution with
regard to cardiovascular health effects.
Methods: 17 never-smoker subjects 30–60 years of age, with stable type 2 diabetes but otherwise healthy, inhaled
either filtered air (0–10 particles/cm3) or elemental carbon UFP (~107 particles/cm3, ~50 ug/m3, count median
diameter 32 nm) by mouthpiece, for 2 hours at rest, in a double-blind, randomized, crossover study design. A digital
12-lead electrocardiogram (ECG) was recorded continuously for 48 hours, beginning 1 hour prior to exposure.
Results: Analysis of 5-minute segments of the ECG during quiet rest showed reduced high-frequency heart rate
variability with UFP relative to air exposure (p = 0.014), paralleled by non-significant reductions in time-domain heart
rate variability parameters. In the analysis of longer durations of the ECG, we found that UFP exposure increased
the heart rate relative to air exposure. During the 21- to 45-hour interval after exposure, the average heart rate
increased approximately 8 beats per minute with UFP, compared to 5 beats per minute with air (p = 0.045). There
were no UFP effects on cardiac rhythm or repolarization.
Conclusions: Inhalation of elemental carbon ultrafine particles alters heart rate and heart rate variability in people
with type 2 diabetes. Our findings suggest that effects may occur and persist hours after a single 2-hour exposure.
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Many studies have shown associations between both short-
and long-term exposure to air pollution and increased
all-cause morbidity and mortality [1]. Exposures to fine
particles (PM) in ambient air are associated with an
increased risk of cardiovascular events [2-5], and with
changes in several cardiovascular indices, including heart
rate, heart rate variability (HRV), and blood pressure.
However, the precise mechanisms for cardiovascular mor-
bidity secondary to air pollution remain unknown [6].* Correspondence: mark_frampton@urmc.rochester.edu
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unless otherwise stated.Moreover, little is known about effects in potentially
susceptible people such as those with diabetes. People
with diabetes may be at increased risk for health effects
of particulate air pollution [7,8]. The risk of coronary
artery disease in diabetics is 2 to 4 times that of the
general population. Diabetics have impaired endothelial
function, in part due to a functional nitric oxide (NO)
deficiency [9].
Ultrafine particles (UFP, ≤100 nm in diameter) have
been hypothesized to be an important component of PM
with regard to cardiovascular health effects. The physical
characteristics of UFP suggest they may carry reactive
molecules into the lung, and may translocate to other
organs via the blood [10,11]. UFP in the air have a
much higher number concentration and surface aread. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 HRV parameters for subjects with diabetes in this
study, and for healthy, younger, non-diabetic subjects
tested under similar conditions*
Current subjects Non-diabetic subjects
N = 17 N = 23
Age 45.9 (9.5) yr Age 28.5 (7.5) yr
NN (ms) 907 (143) 914 (149)
SDNN (ms) 38 (18) 66 (41)
rMSSD (ms) 33 (23) 65 (57)
HF (ms2) 555 (913) 2380 (4222)
LF (ms2) 436 (533) 1580 (2159)
LF/HF 2.9 (5.5) 2.0 (2.2)
HF (nu) 44 (27) 44 (22)
LF (nu) 43 (22) 49 (21)
*5 min recordings supine at rest prior to air exposure. Non-diabetic data from
subjects in our prior studies [35]. Means (SD).
Vora et al. Particle and Fibre Toxicology 2014, 11:31 Page 2 of 9
http://www.particleandfibretoxicology.com/content/11/1/31than larger particles at the same mass concentration.
For example, in order to achieve a low airborne mass
concentration of 10 μg/m3, 2.4×106 20 nm UFP/cm3
are required compared to 1 particle/cm3 of 2.5 μm particles
[12]. UFP also have a higher fractional pulmonary depos-
ition than fine particles [13,14]. UFP have been shown to
cross cell membranes, enter cells, and enter the systemic
circulation, although transport beyond the lung has not
been definitively shown in humans [15]. It has been hy-
pothesized that UFP deliver reactive oxygen species to the
vascular endothelium, resulting in oxidative stress, with
increased production of pro-inflammatory substances and
reduced anti-oxidant capacity, all contributing to endothe-
lial dysfunction and increased atherogenesis [16-18].
Despite these concerns, there are relatively few data
on the health effects of exposure to UFP. A recent
expert panel report [19] found a relative paucity of
epidemiological and clinical data specific for UFP, in
part because of limited ambient monitoring, marked
spatial variability in UFP concentrations, and technical
challenges in performing clinical exposure studies. The
report cited a need for additional controlled laboratory
exposure studies that target UFPs of known source and
chemical composition.
The aim of this study was to determine, in subjects
with type 2 diabetes, the effects of inhalation of ultrafine
particles consisting of elemental carbon (as surrogates for
UFP of combustion origin) on a series of electrocardiogram
(ECG) parameters describing changes in HRV; repolari-
zation duration, morphology, and variability; and the ST
segment. To date, there have been no clinical studies
that have evaluated ECG changes after exposure to UFP
in diabetics. We hypothesized that controlled exposure
to laboratory generated carbon UFP in people with type 2
diabetes alters cardiac function detectable via continuous
ECG. UFP exposure reduced high-frequency heart rate
variability, and unexpectedly increased the average
heart rate 24 to 48 hours after exposure, when com-
pared with air exposure. We previously described UFP




There were 19 subjects (9 men and 10 women) enrolled
in the study and all subjects underwent exposures to
both clean air and laboratory generated UFP. The charac-
teristics of these subjects have been described previously
[16]. The mean ± SD age was 45.9 ± 9.5 years ranging from
31 to 59 years. They had type 2 diabetes diagnosed for
4.4 ± 5.2 years. 12 subjects managed their diabetes with
oral agents (glipizide, glyburide, metformin, pioglitazone),
2 with insulin, 2 with insulin and an oral agent, and 3 with
diet alone. Eight of the subjects were on medication forhypertension (hydrochlorothiazide, valsartan, lisinopril,
ramipril). HbA1c levels ranged from 5.6 to 11.0% with
mean ± SD 7.6 ± 0.3%. For technical reasons, ECG data
were not available for 2 of the 19 subjects.
ECG changes during prespecified 5-minute segments
Table 1 shows selected ECG parameters at baseline
prior to clean air exposure in the current subjects. Also
provided for reference are the same parameters, measured
under similar conditions, in healthy, younger, non-diabetic
subjects from a prior study in our laboratory. SDNN
(standard deviation of normal-to-normal sinus beat in-
tervals), rMSSD (root mean square of successive differ-
ences in NN intervals), HF (high frequency power,
0.15–0.40 Hz) and LF (low frequency power 0.04–0.15 Hz)
were lower in the older, diabetic subjects, as expected.
The heart rate (inverse of the normal-to-normal beat, or
NN, interval) increased 21 and 45 hours after exposure to
both clean air and UFP, compared with earlier time points
(Figure 1A). The increase was slightly but not significantly
greater after UFP, beginning during the night after expos-
ure, and persisting at the 21- and 45-hour time-points
(mixed models, p = 0.09). There were no differences in
heart rate at 0 or 3.5 hours after exposure. The increases
in heart rate were associated with decreases in pNN50
(proportion of NNs that differ by more than 50 ms, di-
vided by the total number of NNs) and rMSSD; reductions
were greater following UFP than air exposure, but not
significantly so (Figure 1B-C). The HF component of the
frequency-domain spectrum of HRV decreased significantly
with UFP exposure (mixed models, p = 0.014) (Figure 1D),
without a significant change in the LF/HF ratio. Other
components of the frequency-domain HRV analysis did
not show clear differences.
In the 5-minute monitoring segments, there were no




Figure 1 ECG changes recorded during pre-specified 5 minute segments. Mean ± SE change from pre-exposure baseline in heart rate (A),
pNN50 (B), rMSSD (C), and HF (D) in subjects exposed to elemental carbon UFP (solid boxes) and filtered air (open circles), during and at specified time
intervals after exposure. The insets show actual baseline values. P-value is for mixed models main effect of exposure.
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rected for heart rate. There were no significant changes
in T wave amplitude or T wave complexity, or in the ST
segments.
ECG changes during extended monitoring periods
In the analyses of the extended monitoring periods (0–9,
9–24, 24–48 hours from the beginning of exposure), the
0–9 hour recording interval was used as the baseline for
comparison with the subsequent intervals.
Similar to the findings with the 5-minute segments,
UFP exposure increased the heart rate to a greater ex-
tent than air exposure (Figure 2A), and the differences
were statistically significant (mixed models, p = 0.045).
This was paralleled by lower SDNN, pNN50, and
rMSSD after UFP exposure, although none were signifi-
cant (Figure 2B-D). There were no significant changes in
QTc interval and T wave amplitude, markers of ventricu-
lar repolarization.
The long-term recordings also showed small non-
significant reductions in the ST segments after UFP ex-
posure, consistently in all three leads (Figure 3). There
were a few marginally significant gender and age inter-
actions in the secondary analysis, but overall there wasno convincing evidence for consistent differences by
age or gender.
Our subjects had very few arrhythmias or premature
cardiac beats, as expected because they were required to
have a normal baseline ECG. There was no evidence for
an increase in arrhythmias following UFP exposure
compared with air exposure. Similarly, we found no
evidence for effects on heart rate turbulence or decel-
eration capacity, although the rarity of abnormal beats
severely limited our analysis of those parameters.
The blood pressure and heart rate measurements taken
with the automated device did not differ significantly
between UFP and air exposure, although the heart rate
increased about 2 beats per minute more after UPF
than after air at the last 2 time points (p = 0.14), similar
to the 5-minute ECG data (Figure 1).
Discussion
Several epidemiological studies suggest that diabetes
confers increased risk for health effects from air pollution
exposure [7,8,19]. We previously reported that UFP ex-
posure transiently increased blood platelet activation
and levels of circulating von-Willebrand factor [16],
consistent with effects on vascular endothelium that
Figure 2 ECG changes during longer monitoring periods. Mean ± SE change from first monitoring period (0–9 hours, which included the
exposure and first few hours afterward) to subsequent 2 monitoring periods, in heart rate (A), SDNN (B), pNN50 (C), and rMSSD (D) in subjects
exposed to elemental carbon UFP (solid boxes) and filtered air (open circles). The insets show actual mean values for the 0–9 hours monitoring
period, which was used as the baseline. P-value is for mixed models main effect of exposure.
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dysfunction, associated with reductions in both time
and frequency domain variables of HRV [21]. Impaired
parasympathetic autonomic function reduces vagal tone,
which can blunt the high-frequency HRV response. As
shown in Table 1, ECG parameters at baseline in our sub-
jects with diabetes differed from healthy, younger, nondia-
betic subjects in our prior studies. These findings indicate
that cardiac physiology and autonomic control of the
heart are altered in people with diabetes, potentially in-
creasing susceptibility to air pollution.
In otherwise healthy people with type 2 diabetes, we
found that inhalation of elemental carbon UFP while
resting caused a delayed increase in heart rate and a reduc-
tion in HF HRV, in comparison with clean air exposure.
There were also small non-significant reductions in
pNN50, rMSSD, and SDNN associated with UFP expos-
ure. We found no convincing effects on parameters of car-
diac repolarization or cardiac rhythm. In the prolonged
recordings, there were small ST depressions in all 3 of the
precordial leads that were analyzed, but none of the
changes were statistically significant. These findings pro-
vide further evidence of an effect of UFP inhalation on the
autonomic nervous system in people with diabetes, with
reductions in vagal relative to sympathetic influences.The UFP influence on heart rate was delayed in our
study, and appears to be an accentuation of the increase
in heart rate that occurred as the subjects left the Clinical
Research Center and returned to their home environment.
As shown in Figures 1A and 2A, the mean heart rate in-
creased 24 and 48 hours after both air and UFP exposure,
probably reflecting increased physical activity and stress
associated with the subjects’ return home. The increase in
heart rate was greater following UFP exposure then air.
The decreases in HF HRV (Figure 1D), and the trends to-
ward decreases in the other markers of HRV associated
with UFP exposure (Figures 1B,1C, and 2B,2C,2E), were
most pronounced during the night following the exposure,
when subjects were presumably sleeping. Parasympathetic
influences predominate during sleep, slowing the heart
rate and increasing heart rate variability [22]. In our study,
this increase in parasympathetic tone appeared to be
blunted following UFP exposure. We postulate that, in
diabetics who have abnormal autonomic function, UFP
exposure further shifts autonomic balance toward sympa-
thetic and away from parasympathetic influences. The delay
in the effects on heart rate suggests this is not a direct effect
of particles on nerve endings within the respiratory epithe-
lium, but a response to a cascade of events, the nature of
which is incompletely understood at this time.
Figure 3 ECG changes during longer monitoring periods.
Mean ± SE change from first monitoring period (0–9 hours, which
included the exposure and first few hours afterward) to subsequent
2 monitoring periods, in the ST segment of the ECG for lead 2 (A),
lead V2 (B), and lead V5 (C), in subjects exposed to elemental
carbon UFP (solid boxes) and filtered air (open circles). The insets
show actual mean values for the 0–9 hours monitoring period.
Vora et al. Particle and Fibre Toxicology 2014, 11:31 Page 5 of 9
http://www.particleandfibretoxicology.com/content/11/1/31One could speculate regarding a number of pathways
for delayed effects on heart rate. Some of our subjects
were obese and could have had sleep apnea. It is possible
that the brief UFP exposure altered sleep dynamics or
worsened sleep-disordered breathing in the nights im-
mediately following exposure, thereby blunting the
normal increase in parasympathetic tone that occurs
during sleep [23]. Increased systemic inflammation as
a result of UFP exposure could alter autonomic tone,
although we found no increases in the circulating in-
flammatory marker C reactive protein in these subjects
[16]. The small, nonsignificant decreases in the ST seg-
ment (Figure 3) could be consistent with an effect on
the myocardium, as a result of subtle changes in car-
diac perfusion, afterload, or preload. Changes in atrial
repolarization could also affect the ST segment, but
this is unlikely in the absence of effects on ventricular
repolarization (T wave and QTc). The mean increases
in heart rate were small (approximately 3 beats per mi-
nute) and not clinically important for people without
heart disease. However, even small effects on heart rate
may be clinically important. Most episodes of cardiac
ventricular arrhythmia, or myocardial ischemia, are
preceded by an increase in heart rate [24]. Increases in
heart rate require greater myocardial oxygen consump-
tion, leading to myocardial ischemia in the presence of
obstructing coronary artery disease. A faster heart rate
shortens left ventricular filling times, which may increase
left atrial filling pressures, leading to pulmonary edema in
patients with systolic or diastolic left ventricular failure.
Resting heart rate is a predictor of all-cause and cardiovas-
cular mortality [24], with an increase in mean heart rate of
10 beats/min associated with a 9.8% increase in all-cause
mortality among patients with coronary artery disease
[25]. In middle-aged subjects without clinical heart
disease, increased night-time heart rate is predictive of
increased mortality and cardiovascular risk after adjust-
ment for other cardiovascular risk factors [26]. Our previ-
ous studies in healthy subjects [27-29] suggest that UFP
inhalation subtly alters both systemic and pulmonary vas-
cular function. Such effects in people with critical cardiac
disease could contribute to the observed associations
between PM exposure and cardiovascular morbidity and
mortality.
Most of the ECG measures in this study did not dif-
fer significantly between air and UFP exposure, includ-
ing time-domain indicators of HRV (rMSSD, SDNN,
pNN50), cardiac repolarization (QTc, T wave ampli-
tude), ischemia (ST segment), or arrhythmia. The auto-
nomic dysfunction associated with diabetes may have
reduced the ability of these subjects to respond with
further reductions in HRV. Also, subjects with known
cardiovascular disease or coronary artery disease were
excluded.
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PM on ECG parameters. Some epidemiology and panel
studies have shown small effects of PM on heart rate
[30-34], but most have not. We previously studied ECG
changes after exposure of healthy subjects to laboratory
generated ultrafine carbon particles and clean air [35].
We found no effects on heart rate, and generally non-
significant effects on HRV, cardiac repolarization, and
the ST segment, with trends suggesting increased para-
sympathetic tone with UFP exposure. Samet et al. [36]
studied 19 young, healthy subjects exposed to concen-
trated ambient ultrafine particles and clean air, with inter-
mittent exercise. They found increased frequency-domain
markers of HRV, indicating elevated, rather than reduced,
vagal (parasympathetic) input to the heart, consistent with
our studies with laboratory generated particles in healthy
subjects. In contrast, Gong et al. [37] found no convincing
effects of concentrated ambient UFP, with intermittent
exercise, on heart rate or HRV in healthy and asthmatic
subjects. Controlled clinical studies in young, healthy
subjects of concentrated ambient fine particles, and
diesel exhaust [38,39], have shown no consistent effects
on HRV. However, studies in elderly subjects have shown
reductions in HRV in response to concentrated ambient
fine particles [40]. Most clinical studies have not looked
beyond 24 hours after exposure.
The bulk of evidence that PM exposure reduces HRV
comes from panel studies of exposure to ambient air
pollution, involving older subjects and those with heart
disease. For example, Henneberger and colleagues [41]
found air pollution effects on cardiac repolarization dur-
ation, morphology, and variability in 56 male patients
with ischemic heart disease. Pope et al. [42] found reduc-
tions in HRV associated with increases in concentrations
of particulate matter less than or equal to 2.5 μm (PM2.5)
in elderly subjects. Rich et al. [43] studied 76 patients
in a cardiac rehabilitation program who had a recent
myocardial infarction or unstable angina. Exposures to
fine particles and UFP were associated with decreases
in parasympathetic modulation, prolongation of late
repolarization duration, increased blood pressure, and
systemic inflammation. In 28 elderly subjects in Boston,
ambient PM2.5 exposure was associated with decreased
rMSSD and pNN50 [44]. There were stronger effects of
black carbon on SDNN in subjects with previous myocar-
dial infarction. Associations with heart rate were not re-
ported. Exposures to ambient air pollution while riding in
a car reduced HF HRV in 21 people with type 2 diabetes
[45], although associations of changes in HF HRV with in-
dividual pollutant concentrations in the vehicle were not
significant.
To the best of our knowledge, this is the first clinical
study of the cardiac effects of exposure to UFP in people
with diabetes. The strengths of our study include use ofa potentially susceptible, under-studied population; the
double-blind, randomized, crossover design; housing of
the subjects in a controlled environment overnight prior to
exposure; and controlled exposures to well-characterized
elemental carbon UFP as a surrogate for ambient UFP. In
addition, continuous ECG recordings for 48 hours allowed
assessment of delayed effects. The limitations include those
inherent in human clinical studies [46], with a relatively
limited number of study subjects, short term exposures,
and possible confounding effects of ambient pollutant ex-
posures prior to the experimental exposures. Exposures
were performed at rest, and effects may differ with exercise.
In addition, our study utilized laboratory generated pure
elemental carbon UFP, which differ from ambient UFP.
Our elemental carbon particles may underestimate the po-
tential effects of ambient UFP, which represent a complex
mixture of chemical species, including organics. However,
we feel that studies such as ours using surrogates for am-
bient UFP have a role in helping to understand UFP health
effects. Ultrafine particle concentrators do not efficiently
concentrate the smallest of the ambient UFP size fraction,
and probably cause alterations in surface chemistry of the
particles that do get concentrated. Soluble particles do not
get concentrated, and volatile surface components are lost.
Thus, concentrated particles must also be considered im-
perfect surrogates of ambient UFP. The other alternative
is studying people undergoing real-world exposures, as in
panel studies. Here the exposures involve complex mix-
tures of pollutants that include larger particles and gases
that vary continuously in concentration and composition,
and it is impossible to completely sort out the role of UFP
in causing any observed effects. Understanding of health
effects of UFP exposure requires synthesis of data from
various approaches, including clinical studies of laboratory
generated and concentrated ambient UFP, panel studies of
ambient exposures, epidemiology, and animal exposure
studies.
While exposure mass concentrations of ~50 μg/m3 used
in this study were relevant to ambient PM exposures, the
exposure number concentrations were substantially higher
than those in most ambient settings. Nevertheless,
UFP number concentrations on busy highways can
reach peaks within an order of magnitude of those
used in this study [47].
Conclusions
Inhalation of elemental carbon ultrafine particles alters
heart rate and heart rate variability in people with type 2
diabetes, and suggests that effects may occur and persist
many hours after the end of the exposure. These find-
ings are consistent with epidemiology studies showing
increased risk of PM exposure in people with diabetes,
and provide a potential mechanism for adverse cardio-
vascular effects.
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Study population
The study was approved by Research Subjects Review
Board of the University of Rochester Medical Center,
and by the US Environmental Protection Agency Human
Subjects Research Review Official. Informed, written
consent was obtained from all subjects. We recruited 19
subjects who were never-smokers, 30–60 years of age,
with type 2 diabetes, as defined by the World Health
Organization [48]. We attempted to balance the subjects
by gender and age (30–45 vs. 46–60 years). Subjects were
required to have stable diabetes with no changes in medica-
tions for at least three months prior to entry, and they con-
tinued on the same regimen during the study. Exclusion
criteria included history of clinical cardiovascular disease,
cardiac arrhythmias, major organ dysfunction, uncontrolled
hypertension, frequent hypoglycemia, statin-type lipid low-
ering medications, use of β-adrenergic blocker medications,
or a history of occupational exposure to particles (e.g. weld-
ing, mining, foundry work). Subjects were asked to avoid
non-steroidal anti-inflammatory drugs and phosphodiester-
ase enzyme inhibitors during the study.
Protocol
The exposure protocol has been previously described
[16]. This was a double-blind, randomized, crossover
study design. Subjects were admitted to the University
of Rochester Clinical Research Center (CRC) the day
prior to exposure and stayed overnight, to reduce con-
founding from exposure to outdoor air pollution. The
following morning, a 12-lead ECG monitoring device
was affixed (see below), blood pressure and heart rate
were measured in the seated position using an automated
device, and then the subject inhaled either filtered air
(0–10 particles/cm3) or elemental carbon UFP (~107
particles/cm3, ~50 ug/m3, count median diameter
32 nm) by mouthpiece, for 2 hours at rest. Blood pres-
sure was measured again 30 minutes and 3.5 hours
after exposure. Subjects left the CRC approximately
6 hours after exposure, with instructions to avoid vigorous
exercise or polluted environments between visits. They
returned approximately 24 and 48 hours after exposure
for followup testing, including blood pressure. The alter-
nate exposure occurred at least 3 weeks later, and the
order of exposure was randomized.
Our facility and particle inhalation system have been
described previously [49]. The particles were generated in
argon using an electric spark discharge between graphite
electrodes, in a modified commercial generator (Palas Co.,
Karlsruhe, Germany). This produced particles consisting
of >95% elemental carbon, free of metals and organic
carbon. Particle number (condensation particle counters,
model 3220a; TSI, Inc., St. Paul MN), mass (tapered elem-
ent oscillating microbalance, Rupprecht and Patachnick,Albany, NY), and size distributions (Scanning Mobility
Particle Sizer, model 3071; TSI, Inc.) were monitored.
Continuous ECG
A continuous digital 12-lead ECG was recorded (Mortara
Instruments, Milwaukee, MN), beginning approximately
1 hour prior to exposure, for a total of 48 hours. Data
were recorded on three different cards (0–9 hours, 9–24
hours and 24–48 hours). The first data card (0–9 hours)
included the exposure and approximately 6 hours after ex-
posure. 5-minute ECG analyses were used for detailed
HRV analyses, prior to, immediately after, 3.5 hours after,
during the night after and 21 and 45 hours after exposure.
The daytime 5-minute analysis segments were initiated
after the subject was supine, but not sleeping, for 5 mi-
nutes, in a quiet room in the Clinical Research Center.
These rest periods for the detailed analysis segments pre-
ceded other study procedures.
ECG analyses
Analysis of the 24-hour ECG recordings was performed
using a research version of Mortara’s MISHA software,
yielding several ECG parameters, including beat-to-beat
RR intervals, lead-specific and beat-to-beat ST segment
levels, T-wave amplitude, and T-wave complexity. Next,
an 8-beat-segment average was computed for the QT
interval, adjusted for heart rate with Bazett’s formula
[50]. T-wave complexity, describing morphology of the
T-wave, was measured in each beat by principal compo-
nent analysis (PCA) based on eight original leads, and
averaged over the 5-minute period [51]. Variability of T-
wave complexity was measured as a standard deviation
over the 5-minute period. ST segment analysis focused
on leads II, V2, and V5, using the median ST segment
level over the 5-minute period.
The time-domain HRV parameters SDNN and rMSSD
were calculated for each 5-minute segment of interest,
and for a 16-hour period starting 3.5 hours after exposure.
The following frequency-domain HRV parameters were
computed for each 5-minute segment using a fast Fourier
technique: HF and LF, both expressed in normalized
units, and the LF/HF ratio [52]. We also measured
heart rate turbulence (HRT) and deceleration capacity
(DC) across the whole session, as previously described
[43]. Not all recordings had at least 1 premature ven-
tricular beat (mean 126 ventricular ectopic beats per
recording), so HRT analyses were done on a subset of
recordings. Otherwise, all other outcomes were measured
in all recordings.
Statistics
This study utilized a randomized, two-by-two crossover
design in which each subject was exposed to both particles
and air. The study was balanced for gender. A washout
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cluded to eliminate carry-over effects.
The statistical method used to analyze the endpoints in
this study was based on the method of Jones and Kenward
[53] for the analysis of cross-over trials with repeated mea-
surements within treatment (exposure) periods. There
were two types of covariance patterns among measure-
ments from the same subject: correlations among mea-
surements in the same treatment period at different time
points, and correlations among measurements from differ-
ent treatment periods. We reasonably assumed that the
between- and within-period covariance structures are sep-
arable. To model these two covariance structures, a linear
mixed model was used in which random subject effect
accounted for the between-period dependencies and an
autoregressive lag 1 correlation structure was used for the
within-period dependencies.
Adjustments for the baseline measurements taken at
the start of each session were made by including the
baseline measurement as a term in the model for the
mean response.
We ran two models: The first model examined the
primary hypothesis of treatment (exposure) effects and
contained terms for treatment, period, time, and time-
by-treatment interactions. The second explored whether
the exposure effects differed based on gender and age
(≤45 years vs. > 45 years), and contained terms for treat-
ment, gender, age group, treatment-by-gender interac-
tions, and treatment-by-age interactions.
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